IGKV2D-29 and cancer: It is, however, likely that more trials will be posted to test, in different cancer types and stages, the interventions in which treatments (chemotherapeutic and/or radiotherapeutic) incorporate A2A or A2B receptor antagonists (or dual A2A/A2B receptor antagonists).